EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Rare antigen‐negative red blood cells from pluripotent stem cells for precision transfusion medicine

Naomi Gunawardena, Hyun Hyung An, Randall W Veliquette iD, Edmund Carvalho, Sambit Dalui, Kaoru Takasaki iD, Eric Wafula, Deborah L French, Giulia Pavani, Stella T Chou

Transfusion · 2026-07 · 66 (7) · 1257-1264

DOI: 10.1111/trf.70243 ↗

At a glance

Journal article in Transfusion, published online on 2026-04-24. Written by Naomi Gunawardena and 9 co-authors. Institution: Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: Erythrocytes, Induced Pluripotent Stem Cells, Transfusion Medicine, Pluripotent Stem Cells. 20 references. The full text is freely available (open access, CC BY 4.0). Funded by: Distinguished Chair in Pediatrics, NHLBI NIH HHS, NIH HHS.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Blood bank identification of antibodies against high‐prevalence antigens remains a challenge due to the scarcity of antigen‐negative reagent red cells sourced from blood donors. The MAM antigen, encoded by EMP3 , is one such antigen associated with red cell alloimmunization and hemolytic disease of the fetus and newborn. Study Design and Methods We used CRISPR‐Cas9 gene editing to generate an EMP3 knockout (EMP3KO) induced pluripotent stem cell (iPSC) line from a type O, Rh null parent line, enabling production of rare MAM‐negative red blood cells. Since a prior study suggested that loss of EMP3 may enhance erythroid proliferation, we hypothesized that EMP3KO could both yield a rare reagent cell and potentially improve erythroid expansion to support scalable production. Transcriptomic analysis allowed us to further investigate the effect of EMP3 loss in late erythroblasts.

Results

EMP3KO cells differentiated efficiently into erythroid cells, showing >95% CD235/CD71 co‐expression and orthochromatic erythroblast morphology. Compared to unedited cells, no proliferative advantage was observed, contrasting with prior non‐isogenic cell models. Agglutination assays confirmed complete loss of MAM antigen and demonstrated the diagnostic utility for identifying MAM antibodies. Transcriptomic profiling of EMP3KO erythroblasts revealed expression of key erythroid genes, as well as regulators of proliferation and heme metabolism, was comparable to the parent line.

Discussion

This study demonstrates that iPSC technology combined with gene editing can generate rare antigen‐negative RBCs for immunohematology applications. Beyond MAM, this platform offers a strategy to create additional rare RBC phenotypes, advancing precision transfusion medicine and improving antibody identification against high‐prevalence antigens.

Subjects

MeSH terms (MEDLINE)

ErythrocytesInduced Pluripotent Stem CellsTransfusion MedicinePluripotent Stem CellsHumansErythroblasts

Author keywords

MAM antigenalloimmunizationinduced pluripotent stem cellsrare red blood cells

Authors and institutions

  • Division of Hematology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Department of Cell and Molecular Biology, Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Immunohematology and Genomics Laboratory, New York Blood Center Enterprises, Rye, New York, USA.
  • Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
  • Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.

ORCID profiles: Randall W Veliquette, Kaoru Takasaki

Funding

  • Distinguished Chair in Pediatrics
  • NHLBI NIH HHS
  • NIH HHS
  • Children's Hospital of Philadelphia Breakthrough Funds
  • Mizuno Funds
  • National Institutes of Health
  • Children's Hospital of Philadelphia

Cite

APA

Gunawardena, N., An, H. H., Veliquette, R. W., Carvalho, E., Dalui, S., Takasaki, K., Wafula, E., French, D. L., Pavani, G., & Chou, S. T. (2026). Rare antigen‐negative red blood cells from pluripotent stem cells for precision transfusion medicine. Transfusion, 66(7), 1257-1264. https://doi.org/10.1111/trf.70243

Vancouver

Gunawardena N, An HH, Veliquette RW, Carvalho E, Dalui S, Takasaki K, et al. Rare antigen‐negative red blood cells from pluripotent stem cells for precision transfusion medicine. Transfusion. 2026;66(7):1257-1264. doi:10.1111/trf.70243

BibTeX
@article{Gunawardena2026,
  author = {Gunawardena, Naomi and An, Hyun Hyung and Veliquette, Randall W and Carvalho, Edmund and Dalui, Sambit and Takasaki, Kaoru and Wafula, Eric and French, Deborah L and Pavani, Giulia and Chou, Stella T},
  title = {Rare antigen‐negative red blood cells from pluripotent stem cells for precision transfusion medicine},
  journal = {Transfusion},
  year = {2026},
  volume = {66},
  number = {7},
  pages = {1257--1264},
  doi = {10.1111/trf.70243}
}
Start for free →